Haisco Pharmaceutical has granted Sentivera exclusive rights outside Greater China to develop, manufacture, and commercialize a preclinical small-molecule candidate targeting Type 2 inflammatory diseases.
The Haisco–Sentivera deal includes about $75.9 million in upfront cash and equity, up to $1.46 billion in development, regulatory, and commercial milestones, plus tiered royalties. Its potential value exceeds $1.5 billion. Haisco will retain rights in mainland China, Hong Kong, Macau, and Taiwan.
The candidate recently received China’s IND clearance, allowing clinical development to begin. Sentivera was founded and backed by Population Health Partners and ARCH Venture Partners.
The FDA approved ViiV Healthcare’s Tivicay PD (dolutegravir) for HIV-1 treatment in pediatric patients weighing at least 2 kg, including eligible newborns from birth through four weeks of age.
Tivicay PD is used with other antiretroviral medicines and is the first approved second-generation integrase inhibitor for children in this weight range. The decision was supported by data from 48 newborns and pharmacokinetic analyses.
The approval addresses a major gap in neonatal HIV care by enabling dolutegravir-based treatment for term newborns weighing at least 2 kg. ViiV is majority-owned by GSK, with Shionogi as a shareholder.
Sources:
Haisco licenses pre-clinical drug to US venture for $1.5 billion
U.S. FDA approves ViiV Healthcare's Tivicay PD, helping ...
ViiV Healthcare advances paediatric HIV regulatory submissions ...
ViiV Healthcare advances paediatric HIV regulatory submissions ...
Haisco: Milliarden-Deal für präklinischen Wirkstoff Von Investing.com
FDA extends approval of Tivicay to treat newborns with HIV - Healio
GSK Looks 14.4% Overvalued on GF Value™ Amid New HIV Treatment A
Metsera duo power Sentivera to $1.5B inflammatory disease deal
GSK-owned ViiV wins FDA label expansion for HIV drug Tivicay
La FDA approuve Tivicay PD pour les nourrissons séropositifs dès 2 kg Par Investing.com
FDA Approves Drug to Treat HIV Infection in Newborns
GSK Stock Slips as Tivicay Priority Review Sets Up Busy FDA ...
FDA and EMA applications to expand dolutegravir indication to ...